Aspira Women's Health (AWHL) Stock Analysis & Winston Score

Aspira Women's Health is a small medical diagnostics company focused on helping doctors detect gynecological diseases in women, particularly ovarian cancer and endometriosis. Its main product is OvaWatch, a blood-based test that helps assess whether a woman's pelvic mass is likely to be cancerous, giving doctors more information before deciding on surgery. The company sells primarily to hospitals, gynecologists, and ob-gyn clinics across the United States. Aspira earns revenue by charging for each diagnostic test performed, a model sometimes called fee-per-test or laboratory services revenue. The company operates almost entirely in the U.S. and is quite small, with annual revenues well under $20 million, meaning it is not yet profitable and relies on raising outside capital to fund operations. The key growth driver is expanding the number of doctors and health systems that order its tests, but the main risk is that larger, better-funded diagnostics companies could develop competing products, and continued losses may require the company to raise more money by issuing new shares.